ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jan 26, 2023 13:16 JST
Source:
Prenetics Global Limited
Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating
Target Price at USD7.00
HONG KONG, Jan 26, 2023 - (ACN Newswire) - It is reported that Cantor Fitzgerald initiated coverage on Prenetics Global (PRE.US) with "Overweight" rating and target price at USD7.00.
Cantor Fitzgerald holds a favorable view of the consumer and clinical testing markets, with Prenetics' focus on diagnostic and preventive testing coupled with personalized and primary care facilities to address a global market opportunity of over $200 billion. In addition, Cantor Fitzgerald believes its commercialization strategy in rolling out tests both via B2C and B2B in the future, depending on which avenue will result in the broadest adoption with the lowest amount of operating expenses, is unique and sound. Prenetics looks to add new tests to its platform through acquisitions and partnerships, resulting in faster time to market and a comprehensive healthcare ecosystem in a not-so-distant future.
Meanwhile, with Prenetics' ecosystem coming together and being able to uniquely demonstrate profitability given its lower operating expenses and R&D expenses relative to peers, Cantor Fitzgerald thinks Prenetics' shares are also attractively valued.
In the near term, Prenetics will focus on Hong Kong, Southeast Asia and the UK, where the company has strong leadership teams in place and benefits from little to no competition, most notably in Asia.
Source: Prenetics Global Limited
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TOYOTA GAZOO Racing begins WRC title bid with a legendary challenge
Jan 17, 2025 19:53 JST
Mitsubishi Corporation and JOGMEC Announce Investment in eFuels provider Infinium
Jan 17, 2025 14:35 JST
NEC Listed on the World Index and Asia Pacific Index of Dow Jones Sustainability Indices (DJSI)
Jan 17, 2025 12:47 JST
Mitsubishi Power Reinforces Commitment to Saudi Arabia's Sustainable Energy Future at Saudi Aramco's IKTVA Forum 2025
Jan 16, 2025 16:56 JST
JCB and DOJO partner to help cardmembers enjoy a more seamless payment experience
Jan 16, 2025 11:00 JST
MHI Delivers 60 Cars for the Nippori-Toneri Liner Model 330
Jan 15, 2025 16:38 JST
JCB and Taiwan Rakuten Card Launch New JCB Panda Card
Jan 15, 2025 15:00 JST
Fujitsu, Resona Bank and Saitama Resona Bank launch new web service to simplify home-buying process
Jan 15, 2025 13:13 JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 15, 2025 10:03 JST
18th Asian Financial Forum wraps up successfully
Jan 14, 2025 20:56 JST
Honda Civic Hybrid Named 2025 North American Car of the Year, Making Civic the Most Honored Model in the History of the Award
Jan 13, 2025 17:07 JST
Galaxy Payroll: Driving Innovation in Human Resources Management
Jan 10, 2025 23:35 JST
Honda 2025 Motorsports Program Overview
Jan 10, 2025 20:26 JST
TOYOTA GAZOO Racing Exhibiting at Tokyo Auto Salon 2025
Jan 10, 2025 18:38 JST
Mazda Introduce the All-NEW "Mazda6" Battery EV in Europe
Jan 10, 2025 17:27 JST
JCB unveils a new e-book that empowers merchants and acquirers to harness growth drivers in the European region
Jan 10, 2025 12:00 JST
NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field
Jan 10, 2025 11:37 JST
Outlander PHEV Tops Canada's Plug-In Hybrid EV Sales in 2024
Jan 10, 2025 09:25 JST
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
Jan 08, 2025 17:32 JST
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 08, 2025 12:30 JST
More Latest Release >>
Related Release
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening
June 26 2023 09:37 JST
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology
March 14 2023 22:05 JST
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
March 04 2023 15:40 JST
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
January 11 2023 11:19 JST
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics
December 16 2022 19:57 JST
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
November 30 2022 22:43 JST
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
November 10 2022 21:36 JST
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
September 09 2022 21:54 JST
More Press release >>